Target
Trabectedin
6 abstracts
Abstract
Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan Clinical Oncology Group study JCOG1802 (2ND-STEP).Org: Fukui University School of Medicine,
Abstract
Sarcoma drug approvals in Latin America compared to the FDA and EMA: An analysis by the LACOG Sarcoma Group.Org: Brazilian National Cancer Institute,
Abstract
An update on SOC-1882: A phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.Org: 2811 Wilshire Blvd., Suite 414,
Abstract
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center, City of Hope Comprehensive Cancer Center, UCLA David Geffen School of Medicine,
Abstract
Efficacy and safety of anthracycline combined with alkylating agent for treatment of advanced leiomyosarcoma.Org: Beijing Sanhuan Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,
Abstract
Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).Org: Helios Klinikum Berlin-Buch, Charité–Universitätsmedizin Berlin, Medizinische Fakultät “Carl Gustav Carus“ der TU Dresden, Universitätsklinikum Würzburg, Universität Heidelberg,